World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
45362
World Ranking
7869
National Ranking
4101

Overview

Maureen D. Mayes is affiliated with The University of Texas at Austin in the United States. The primary focus of their research lies within the field of Medicine, with extensive work covering specialized subfields such as Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Epidemiology, Immunology, and Dermatology. Their scholarly output reflects a significant contribution to systemic sclerosis and related diseases and other overlapping areas.

Their main topics of study include systemic sclerosis and related diseases, interstitial lung diseases and idiopathic pulmonary fibrosis, inflammatory myopathies and dermatomyositis, mast cells and histamine, dermatologic treatments and research, autoimmune bullous skin diseases, and eosinophilic disorders and syndromes. This thematic concentration aligns with their publication record across multiple respected venues.

Frequent publication venues where Mayes's work appears include:

  • Annals of the Rheumatic Diseases
  • Arthritis & Rheumatology
  • Arthritis Care & Research
  • ACR Open Rheumatology
  • Lara D. Veeken

Mayes has collaborated extensively with several researchers, reflecting sustained academic partnerships that contribute to their research output. Frequent co-authors include:

  • Shervin Assassi
  • Brett D. Thombs
  • Linda Kwakkenbos
  • Vanessa L. Malcarne
  • Leland W.K. Chung

The following recent papers exemplify the scope and focus of their contributions:

  • Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial, 2021, The Lancet Respiratory Medicine
  • Expert consensus on the management of systemic sclerosis-associated interstitial lung disease, 2023, Respiratory Research
  • Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis, 2020, Arthritis & Rheumatology
  • Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study, 2020, Journal of Psychosomatic Research
  • Machine learning predicts stem cell transplant response in severe scleroderma, 2020, Annals of the Rheumatic Diseases

Best Publications

  • 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson

  • Cyclophosphamide versus placebo in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Jonathan Goldin

  • Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

    Oliver Distler;Martina Gahlemann;Toby M Maher

  • Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population

    Maureen D. Mayes;James V. Lacey;Jennifer Beebe-Dimmer;Brenda W. Gillespie

  • Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis

    P Clements;P Lachenbruch;J Siebold;B White

  • Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Donald P. Tashkin;Michael D. Roth;Philip J. Clements;Daniel E. Furst

  • Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

    J. H. Korn;Maureen D Mayes;M. Matucci Cerinic;M. Rainisio

  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

    K. M. Sullivan;E. A. Goldmuntz;L. Keyes-Elstein;P. A. McSweeney

  • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Michael D. Roth

  • Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

    Marco Matucci-Cerinic;Christopher P Denton;Daniel E Furst;Maureen D Mayes

  • Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

    P. J. Clements;P. A. Lachenbruch;J. R. Seibold;B. Zee

  • Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis

    Dinesh Khanna;Daniel E. Furst;Philip J. Clements;Yannick Allanore

  • Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

    Christopher P. Denton;Peter A. Merkel;Daniel E. Furst;Dinesh Khanna

  • Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study

    Fredrick M. Wigley;Robert A. Wise;James R. Seibold;Deborah A. McCloskey

  • Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis

    L. Van Bon;L. Van Bon;A. J. Affandi;A. J. Affandi;J. Broen;J. Broen;R. B. Christmann

  • Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

    Timothy R.D.J. Radstake;Olga Y Gorlova;Blanca Rueda;Jose Ezequiel Martin

  • High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial

    Philip J. Clements;Daniel E. Furst;Weng Kee Wong;Maureen Mayes

  • Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

    Peter A. Merkel;Peter A. Merkel;Karen Herlyn;Richard W. Martin;Jennifer J. Anderson

  • Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

    James R. Seibold;Joseph H. Korn;Robert Simms;Phillip J. Clements

  • Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High‐dose versus low‐dose penicillamine trial

    Philip J. Clements;Eric L. Hurwitz;Weng Kee Wong;James R. Seibold

Frequent Co-Authors

Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Dinesh Khanna
Dinesh Khanna University of Michigan–Ann Arbor
Frank C. Arnett
Frank C. Arnett The University of Texas Health Science Center at Houston
Virginia D. Steen
Virginia D. Steen Georgetown University
John D. Reveille
John D. Reveille The University of Texas Health Science Center at Houston
John Varga
John Varga University of Michigan–Ann Arbor
Christopher P. Denton
Christopher P. Denton University College London
Philip J. Clements
Philip J. Clements University of California, Los Angeles
Fredrick M. Wigley
Fredrick M. Wigley Johns Hopkins University
Filemon K. Tan
Filemon K. Tan The University of Texas Health Science Center at Houston

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA offers diverse pathways beyond the traditional MD. Many students and working professionals now pursue flexible online degrees to advance their healthcare expertise or shift career tracks.

For those interested in healthcare leadership, the top cahme accredited mha programs provide rigorous training in health administration, fully online, and with respected accreditation. Nurses seeking to upgrade qualifications without pausing their careers can enroll in online rn-bsn programs without clinicals. These programs eliminate clinical requirements for experienced RNs—saving time while boosting credentials.

For advanced practice, Doctor of Nursing Practice degrees are increasingly popular. Options such as the shortest dnp program online allow professionals to achieve the terminal degree in nursing efficiently. Those seeking a manageable workload can explore the easiest dnp programs, designed with flexibility for busy practitioners.

These alternative online degrees open doors for healthcare professionals to climb the career ladder or seamlessly enter new specialties, all while balancing work and life commitments.

Best Scientists Citing Maureen D. Mayes

Trending Scientists

Recently Published Articles